PARSIPPANY, N.J., June 16 Fontus Pharmaceuticals, Inc., aspecialty pharmaceutical company focused on nephrology and endocrinology,announced today that it has acquired ROCALTROL(R) (calcitriol) from RocheLaboratories Inc. ROCALTROL is a vitamin D analog prescribed by nephrologistsfor the management of hyperparathyroidism and resultant metabolic bone diseasein patients with moderate to severe chronic renal failure (CRF) and byendocrinologists for the management of hypocalcemia in patients withpost-surgical hypoparathyroidism, idiopathic hypoparathyroidism andpseudohypoparathyroidism.
About ROCALTROL(R) (calcitriol)
ROCALTROL, available as capsules and as an oral solution, is the mostpotent metabolite of vitamin D available and is active in regulating theabsorption of calcium from the gastrointestinal tract and its utilization inthe body. The calcitriol in ROCALTROL is believed to be the active hormonewhich exerts vitamin D activity in the body. ROCALTROL improves calciumabsorption in patients who have severe vitamin D deficiencies commonlyassociated with CRF, chronic kidney disease (CKD), end-stage renal disease(ESRD) or primary hypothyroidism.
ROCALTROL therapy should always be started at the lowest possible dose andshould not be increased without careful monitoring of serum calcium. In orderto avoid hypercalcemia and related conditions, the optimal daily dose ofROCALTROL must be carefully determined for each patient. The safety andeffectiveness of ROCALTROL in pediatric predialysis patients is based onevidence from adequate and well controlled studies of ROCALTROL in adults withpredialysis chronic renal failure and additional supportive data fromnon-placebo controlled studies in pediatric patients. Specific doses ofROCALTROL are recommended for pediatric predialysis patients. These and otherprecautions and warnings may be found in the package insert for ROCALTROL.
About Fontus Pharmaceuticals
Fontus Pharmaceuticals, Inc. ("Fontus") is a specialty pharmaceuticalcompany distinguished by its strategy to acquire and market FDA-approvedproducts used in the fields of nephrology and endocrinology. Fontus focuseson mature products with widely accepted clinical value and brand loyalty.Fontus re-invigorates promotion and in some cases reformulates products tooptimize clinical benefit. Fontus is the second new specialty pharmaceuticalcompany to be formed with an investment from the private equity fund, KonandaPharma Fund I, L.P. For more information, please visit www.fontuspharma.com.
About Konanda Pharma Fund I, L.P.
Konanda Pharma Fund I, L.P. is a private equity fund that founds andinvests in portfolio companies that acquire mature prescription drug brandsthat offer important therapeutic benefits. For more information, pleasevisit www.konanda.com.
SOURCE Fontus Pharmaceuticals, Inc.